Altre lingue Bristol-Myers Squibb Company Börse Stuttgart

Azioni

BRM

US1101221083

Tempo reale stimato Tradegate Altri mercati azionari 08:34:29 19/06/2024			Variaz. 5gg	Var. 1 gen.
38 ^EUR	+0,90%		-5,70%	-19,11%

18/06	Bristol Myers Squibb nomina Michael R. McMullen Direttore indipendente e membro del Comitato di revisione, con effetto dal 1° luglio 2024	CI
18/06	Immunocore randomizza il primo paziente nello studio di fase 3 del trattamento combinato del melanoma cutaneo	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Bristol Myers : l'ex-CEO d'Agilent rejoint le conseil	07:11
Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors	18/06
Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024	18/06
Immunocore Randomizes First Patient in Phase 3 Trial of Cutaneous Melanoma Combination Treatment	18/06
Bristol Myers Squibb Keeps Quarterly Dividend at $0.60 a Share, Payable Aug. 1 to Shareholders of Record July 5	18/06
Bristol Myers : dividendes décidés par le conseil	18/06
Bristol Myers Squibb Announces Dividend	18/06
Bristol Myers Squibb Declares A Quarterly Dividend, Payable on August 1, 2024	18/06
Bristol Myers : approbation de la FDA pour un traitement	14/06
Bristol-Myers Squibb's Augtyro Gets FDA Accelerated Approval for Treatment of Solid Tumors	13/06
Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval	13/06
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors	13/06
Bristol Myers Squibb Announces U.S. Food and Drug Administration Approves Augtyro (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors	13/06
Evotec to Receive $20 Million Under Neuroscience Partnership with Bristol Myers Squibb	12/06
Evotec Gets $20 Million Milestone Payment in Neurodegenerative Disease Collaboration With Bristol Myers Squibb	12/06
Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb	12/06
Evotec erhält Forschungszahlung von 20 Mio USD von Myers Squibb	12/06
ABL Bio, BMS Collaborate on Gastric Cancer Treatment Trial	10/06
Geron shares surge after U.S. FDA approves blood disorder drug	07/06
I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers	05/06

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

In prima pagina

Il CEO di Bristol-Myers dice che l'azienda è in fase di transizione

09 gennaio 2024 alle 19:06